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SUMMARY In this retrospective study, data on 241 atopic patients 
treated with specific cutaneous immunotherapy during the 1985-2006 
period at Allergy Clinic, University Department of Dermatology and 
Venereology, were reviewed. The following diagnoses were recorded: 
atopic dermatitis, pure or in combination with allergic rhinitis or 
allergic bronchitis, or allergic bronchitis and asthma, allergic rhinitis, 
allergic conjunctivitis, urticaria, and Quincke’s edema. The aim was 
to retrospectively analyze clinical efficacy and laboratory findings in 
atopic patients undergoing specific immunotherapy. Before specific 
immunotherapy administration, eosinophil count, immunoglobulins, 
skin prick test, total IgE (RIST) and specific IgE (IgE UniCAP) 
were determined. The following allergens were included in specific 
immunotherapy: Dermatophagoides pteronyssinus, house dust 
mite (mixed or separately), mixed and single pollens (grass, tree, 
weed), feather, and animal dander. The most frequent allergens in 
241 atopic patients were grass pollen mixture, Dermatophagoides 
pteronyssinus, ragweed, tree pollen mixture, cocksfoot, birch, animal 
dander, and feather. Treatment efficacy was demonstrated after 3 
years of continuous therapy by clinical evaluation and with the same 
diagnostic procedure. After several months of therapy, initial clinical 
improvement was noticed in atopic dermatitis patients as well as in 
patients with respiratory diseases that were sensitive to airborne 
allergens. According to literature, specific immunotherapy was used 
as a treatment option, which may affect the natural course of allergic 
diseases. It reduces development of asthma in patients with allergic 
rhinitis and prevents the onset of new sensitizations.
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INTRODUCTION
 Allergen specific cutaneous immunothera-
py (SCIT) is the first-line management in atopic 
patients sensitive to airborne allergens. In this 
retrospective study, we evaluated the efficacy 
of SCIT in different groups of atopic patients as 
well as in pure atopic dermatitis patients as a 
valuable option for a selected group of atopic 
patients (1).   
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 Recently, immune mechanisms underlying clin-
ical efficacy of SCIT in human allergic diseases 
have aroused considerable interest. In the last 
years, it has been demonstrated that SCIT may 
influence a deviated immune response of allergic 
patients towards normal immunity (2). In this study, 
serum total and specific IgE directed against com-
mon airborne allergens were evaluated, and se-
rum eosinophil count, total immunoglobulins (IgA, 
IgM, IgG) and correlation between the skin prick 
test (SPT) and IgE in atopic patients were deter-
mined.
MATERIAL AND METHODS
 During the 1985-2006 period, 241 atopic pa-
tients underwent SCIT at Allergy Clinic, Univer-
sity Department of Dermatology and Venereology, 
Zagreb University Hospital Center and School of 
Medicine. According to clinical diagnosis, SCIT 
was administered in patients with atopic dermati-
tis (AD), pure or in combination with allergic rhinitis 
(AR) and/or allergic bronchitis (AB), allergic bron-
chitis and asthma, allergic rhinitis (AR+AB), allergic 
conjunctivitis (AC), urticaria, and Quincke’s edema 
(U+QE) (Fig. 1). Atopic patients were clinically 
evaluated, free from disease relapses and without 
any immunotherapy procedure (1,3). The SCIT AD 
group of patients consisted of 88 AD pure patients, 
30 AD+AR and 3 AD+AB patients in comparison 
with 87 AR, 16 AC, 12 AB and 4 U+QE respiratory 
allergy patients. All AD patients had intense pruri-
tus, excoriated skin lesions and moderate disease. 
 Before treatment, the following measurements 
were performed: immunoglobulins, eosinophil 
count, SPT, total IgE and specific IgE, according to 
standard procedure. SPT standardized allergens 
were supplied by Zagreb Institute of Immunology, 
according to the European standard. A standard 
procedure of SPT was performed (3-5). 
 The immediate type hypersensitivity was dem-
onstrated with allergens for SPT. We started with 
histamine as positive control and buffer solution 
as negative control. After 20-25 minutes, we read 
positive reactions: weal and flare, from +1 to +4 
(3).
 In this study, serum total IgE and specific IgE 
antibodies directed against common airborne al-
lergens were evaluated before and after 36 months 
of SCIT therapy by use of the Radio Immunosor-
bent Test (RIST), FluoroImmuno Assay (FIA), 
FluoroEnzymeImmunoAssay-CAP System (FEIA-
CAP), and RadioAllergosorbent Test (RAST) and 
CAP System RAST for determination of specific 
IgE antibodies (3).
 The Pharmacia UniCAP system FEIA reagents 
were used for quantitative measurement of se-
rum total or specific IgE antibodies, with reading 
in classes 0 to 6. Normal total IgE range was 100 
kU/L. Specific IgE range (kUA/L) was from class 0 
to 6 (Table 1).
 Immunoglobulins (IgA, IgM, IgG) were deter-
mined by the immunoturbidimetric method (Cobas 
Roche 600). Eosinophil count was determined in 
percentage of blood count.
Table 1. Specific IgE range (kU/l) – UniCAP
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 The following allergens were used for specific 
immunotherapy according to WAO taskforce (4):
 - Dermatophagoides pteronyssinus, house dust 
   mite (mixed or separately),
 - mixed pollens (grass, tree, weed)
 - single allergens: 
	 	 o	grass (cocksfoot, timothy, rye)
	 	 o	tree (hazel, birch, black pine, locust, plane- 
       tree, poplar, lime, olive, elder, willow, oak)
	 	 o	feather, animal fur
RESULTS
 In this retrospective study including data on 
241 atopic patients, results of clinical evaluation 
and laboratory tests confirmed the efficacy of 
SCIT. We analyzed correlation between SPT, to-
tal and specific IgE UniCAP tests (Table 3, Fig. 
3). The results showed the correlation of SPT with 
specific IgE for grass and weed pollen to be better 
in patients with allergic rhinitis, conjunctivitis and 
bronchitis. There was good correlation in all three 
tests. Patients with atopic dermatitis sensitive to 
Dermatophagoides pteronyssinus showed better 
correlation of SPT with total IgE and clinical ef-
ficacy. In all AD patients, there was a long period 
with relapse of skin lesions (10-15 months). 
 As shown in Figure 2, the most frequent aller-
gens in 241 atopic patients were grass pollen mix-
ture, Dermatophagoides pteronyssinus, ragweed, 
tree pollen mixture, cocksfoot, birch, animal dan-
der, and feather.
 Therapeutic efficacy (less or free from symp-
toms in almost all patients) was noticed after a 
minimum of 3 years of therapy. Very good clinical 
outcome was noticed in patients with atopic re-
spiratory diseases as well as in those with atopic 
dermatitis allergic to aeroallergens (Dermatopha-
goides, mixed pollens: grass, tree, weed). In these 
groups of patients, therapeutic efficacy was first 
proved several months of therapy initiation, as 
also reported by Canonica et al. (4). 
 In one patient, a systemic adverse event was 
recorded (bronchospasm, wheals). Parenteral an-
tiallergic therapy was successfully administered; 
however, specific immunotherapy was discontin-
ued. 
 Due to marked erythema on the photoexposed 
areas (face, neck and hands), two patients gave 
up specific immunotherapy and switched to local 
immunomodulator.
 There was a significant decrease in serum total 
IgE and specific IgE to Dermatophagoides. The 
values of eosinophil count and immunoglobulins 
were within the normal limits both before and after 
SCIT.
 DISCUSSION
 In this ret rospective study including data on 
241 atopic patients, we confirmed the efficacy of 
SCIT, substantiated by our own experience. In a 
future prospective study we will assess the influ-
ence of SCIT on serum level of IFN-γ, IL-4 and 
IL-5 before and after 3-4 years of therapy. Cor-
relation between clinical score and serum level of 
cytokines will be determined. 
 Specific immunotherapy is used for a century 
now and its efficacy is well documented.
 However, as there were no defined standards 
for performing clinical trials with specific immuno-
therapy, the World Allergy Organization gathered 
a group of experts to develop guidelines for the 
methodology of immunotherapy studies. The rec-
ommendations include guidelines for study de-
sign, patient selection, appropriate outcomes and 
statistical processing to be applied in planning and 
performing clinical studies with allergen specific 
Figure 2. Most common allergens in 241 atopic patients according to skin prick test.
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immunotherapy (4). Although the real role of IgE 
in the efficacy of SCIT is not quite clear, it seems 
that IgE is involved in AR, venom allergy and AD 
treated with SCIT.  
 SCIT is a causal treatment for IgE-mediated al-
lergic diseases. It induces long-term tolerance to 
the applied allergens through several immune ef-
fects. Its preventive aspects, especially reduced 
development of bronchial asthma and less new 
allergic sensitizations, have been ever more taken 
in consideration when deciding on SCIT, as also 
proven in this study. 
Table 2. Correlation of skin prick test (SPT), total and specific IgE UniCAP tests in 241 atopic patients 
undergoing specific immunotherapy (1985-2006) before treatment
Number of 
patients 
Diagnosis Most often positive reactions in  
SPTs (+1 to +4)
Total  IgE value 
UniCAP (kU/l)
Specific IgE range  from +1 to +6
87 AR Grass pollen +2, +4
Der p +3, +2
Tree pollen +3
Weed pollen +3
441-1034 Gras pollen +2 (1.70) +4 (50.6)
Der p +3 (8.66) to +5 (70.0)
Tree pollen +3 (12.0) to +4 (21.0) 
Birch +4 (39.40)
Weed pollen +3 to +4
Ragweed +6 (>100.0)
88 AD Der p +4, +3
Grass pollen +3, +2
Timothy +4, +3
Feather +1
Weed pollen +2, +4
Mugwort +3
Tree pollen +2
154 to >4000 Der p +4 (33.9) to+6 (>100.0)
Grass pollen +2 (1.70) to +4 (36.8)
Timothy +4 (30.3)
Feather 0 (<0.35)
Weed pollen +2 (3.13) to +5 (58.2)
Ragweed +5 (59.9)
Tree pollen +3 (4.54) to +6 (>100)








129-2455 Der p +1 (1.42)
Timothy +4 (50.6)
Weed pollen +6 (>100)
Mugwort +4 (60.0)
Tree pollen +6 (>100)
Birch +2 (2.20)
Feather +3 (13.1)







46-1072 Der p +3 (8.66)
Tree pollen +4 (21.0)
Birch +4 (32.4)
Animal dander +2 (2.20)
Grass pollen +3 (12.0)
Cocksfoot +3 (13.1)
Weed pollen +3 (10.8) to +6 (>100.0)




29-797 Ragweed +5 (68.2)
Cocksfoot +2 (2.69)
Oak +3 (4.49)
Der p +2 (2.69)
3 AD+AB Der p +2,+3




36-609 Der p +6 (>100)
Grass pollen +4 (36.8)
Tree pollen +6 (>100)
Weed pollen +2 (3.13) to +5 (58.2)
1 AR+AB Der. p +3
Weed pollen +2,+3
Grass pollen +2
109 Der.p +6 (>100)
Weed pollen +4
Tree pollen +3
4 URT+QE Grass pollen +1
Weed pollen +2, +3
Tree pollen +2,+3
150- 466 Weed pollen +4 (40.4) do +5 (86.7)
Ragweed +3 (10.8)
Tree pollen +2 (2.20) to +4 (21.0)
AR, allergic rhinitis; AD, atopic dermatitis; (AD+AR), atopic dermatitis and allergic rhinitis; AC, allergic conjunctivitis; 
AB, allergic bronchitis and asthma; (AD+AB), atopic dermatitis and allergic bronchitis and asthma; (AR+AB), allergic 
rhinitis and allergic bronchitis and asthma; (URT+QE), urticaria and Quincke’s edema
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 SCIT is indicated in patients with IgE-mediated 
sensitizations with clinical symptoms to allergens 
which do not permit allergen avoidance and are 
available as suitable extracts. Children tolerate 
and benefit from its immunomodulatory effects 
most (5). New routes of administration currently 
considered include sublingual immunotherapy 
(SLIT), demonstrated to be equally efficacious 
and with less side effects and good compliance 
(6). 
 As the high prevalence of allergic adverse events 
during treatment remains one of the main 
Table 3. Correlation of skin prick test (SPT), total and specific IgE UniCAP tests in 241 atopic patients 
undergoing specific immunotherapy (1985-2006) after 36 months of treatment
Number of 
patients 
Diagnosis Most often positive 
reactions in  SPTs (+1 to 
+3)
Total  IgE value 
UniCAP (kU/l)
Specific IgE range  from +1 
to +5
87 AR Grass pollen +1, +3
Der p +2, +1
Tree pollen +1
Weed pollen +1
220-800 Gras pollen +1 to +2 
Der p +1  to +3 
Tree pollen +1  to +2  
Birch +2
Weed pollen +2 
Ragweed +3 
88 AD Der p +2; +1
Grass pollen +1, +1
Timothy +2, +1
Feather 0
Weed pollen +1, +2
Mugwort +1
Tree pollen +1
80 to >2500 Der p +2  to+3 
Grass pollen +1 to +3 
Timothy +2 
Feather 0
Weed pollen +1 to +5 
Ragweed +2 
Tree pollen +1  to +2 
30 AD+AR Der p 0







50-1210 Der p 0 
Timothy +2 
Weed pollen +3 
Mugwort +3 
Tree pollen +3 
Birch +1 
Feather +1 







22-600 Der p +1
Tree pollen +2 
Birch +2 
Animal dander 0 
Grass pollen +1 
Cocksfoot +1 
Weed pollen +1 to +3 




20-200 Ragweed +3 
Cocksfoot +1 
Oak +1 
Der p +1 
3 AD+AB Der p +1, +1




10-300 Der p +3 
Grass pollen +2
Tree pollen +3 
Weed pollen +1 to +3 
1 AR+AB Der. p +1
Weed pollen +1, +1
Grass pollen +1
60 Der.p +3 (>100)
Weed pollen +3
Tree pollen +2
4 URT+QE Grass pollen 0
Weed pollen +1, +1
Tree pollen +1, +1
128-250 Weed pollen +2 to +3
Ragweed +1 
Tree pollen +1 to +2 
AR, allergic rhinitis; AD, atopic dermatitis; (AD+AR), atopic dermatitis and allergic rhinitis; AC, allergic conjunctivitis; 
AB, allergic bronchitis and asthma; (AD+AB), atopic dermatitis and allergic bronchitis and asthma; (AR+AB), allergic 
rhinitis and allergic bronchitis and asthma; (URT+QE), urticaria and Quincke’s edema
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problems, there are some approaches to reduce 
the allergenicity of immunotherapy preparations 
while maintaining immunogenicity. Peptide immu-
notherapy (short synthetic peptides) represents 
major T-cell epitopes of the allergen. The possible 
benefits might be reduction of both the capacity 
to cross-link IgE molecules and activation of mast 
cells and basophils as well as the ease of manu-
facture and standardization (7).
 SCIT or SLIT in atopic dermatitis (AD) is still a 
controversial issue. In our AD patients, SCIT was 
beneficial. A WHO position paper states that im-
munotherapy for AD is only acceptable for clini-
cal trials. However, SCIT seems to be beneficial 
in children and teenagers in particular, for modi-
fication of the natural course of atopic march. As 
for the immunologic parameters in the sera of pa-
tients with AD, a significant decrease in total IgE 
and IgE against aeroallergens was recorded in 
the course of SIT. Our results confirmed this find-
ing. Czarnecka-Operacz and Silny followed ECP, 
IFN-γ, Il-12, Il-4 and Il-5 before and after SCIT (8). 
 SLIT treatment for 6 months was clinically ef-
fective in decreasing asthmatic symptoms and 
medication use in children with mild-to-moderate 
asthma due to mite sensitivity. After 6 months of 
treatment, there was a significant difference in 
nighttime asthma symptom scores and specific 
IgG4 between the SLIT group and placebo group 
(9). In addition, daytime symptom and medica-
tion scores, total IgE, eosinophil count, FEV1 and 
mean evening peak expiratory flow rate reached 
significant differences in SLIT group. No severe 
adverse events were reported (9).
 Another study in children with house-dust mite 
(HDM) induced allergic asthma optimally controlled 
by pharmacologic treatment and mite-avoidance 
measures indicated that SLIT did not provide ad-
ditional benefit, despite a significant reduction in 
allergic response to HDM (10). However, the au-
thors emphasize that the results of this study must 
be viewed in the context where allergen SIT is 
known to modify and induce reduction of asthma 
onset in patients with allergic rhinitis. On the other 
hand, long-term inhaled corticosteroid therapy in 
children does not have a disease-modifying ef-
fect. Therefore, children with early onset of aller-
gic asthma not treated with inhaled steroid therapy 
could be potential candidates for SLIT (10).
 The usefulness of SCIT in patients with atopic 
dermatitis allergic to HDM and allergic sensiti-
zation to HDM was confirmed in a multi-center, 
randomized, dose-response study conducted 
by Werfel et al. They showed that SIT to HDM 
preparation for one year improved eczema in pa-
tients with atopic dermatitis sensitized to HDM al-
lergens and reduced the need of topical cortico-
steroids (11). A similar observation was noted in 
our study.
CONCLUSION
 It is difficult to evaluate the possible effect of 
SCIT; however, its efficacy has been demonstrat-
ed in many study groups of atopic patients as well 
as in our retrospective study. The issue will be ad-
ditionally investigated in future trials. 
 Atopic and allergic diseases are increasing in 
the last decades. Atopic dermatitis is prevalent 
worldwide and Dermatophagoides pteronyssinus 
is the leading causative allergen (2,11). The dis-
ease itself is difficult to treat, especially in com-
bination with respiratory allergy, and is disturbing 
for the patient and his family. At the moment, SCIT 
seems to be a valuable treatment that can both 
prevent new sensitizations and modify the course 
of atopic march. Therefore, we support SCIT as 
the method of choice in atopic patients, as it rep-
resents a worthwhile therapeutic option not only 
for children with respiratory allergy but also for 
adolescents sensitive to aeroallergens. According 
to our experience, SCIT should better be adminis-
tered twice a year (spring and autumn) with pollen 
allergens, and once a year for other inhalant al-
lergens. We intend to launch a prospective study 
with a more extensive spectrum of immunologic 
parameters (IFN-γ, IL-4 and IL-5) before and after 
three years of SCIT to demonstrate the advantag-
es of this therapeutic method.
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